Xconomy.com -- Alnylam Pharmaceuticals had more than $470 million in the bank as of the last official count at the end of June, so it struck me as odd that the Cambridge, MA-based developer of gene-silencing drugs was a presenter along with dozens of cash-starved biotech startups at the MassBio Investors Forum in Boston yesterday. Alnylam and its poorer biotech counterparts made some interesting buzz.
